332 Followers on Owler
Jounce Therapeutics is engaged in the discovery and development of a pipeline of cancer immunotherapy treatments for a range of cancers...
Read moreJounce Therapeutics is engaged in the discovery and development of a pipeline of cancer immunotherapy treatments for a range of cancers...
Read more
2012
PublicIndependent CompanyNASDAQJNCE
News
Jan 02, 2023
Citybizlist
Jounce: Gilead To Acquire All Remaining Rights To Potential First-In-Class Immunotherapy GS-1811 From Jounce Therapeutics
Dec 29, 2022
Seeking Alpha
Jounce: Jounce: Gilead's GS-1811 Buyout Allows A Further Bounce
Dec 29, 2022
Pharmabiz
Jounce: Gilead to buy remaining rights to potential firstinclass immunotherapy GS1811 from Jounce Therapeutics
Dec 28, 2022
PharmaLive
Jounce: Gilead buys out rights to cancer therapy from Jounce for $67 million
Dec 08, 2022
GlobeNewswire
Press Release: Jounce : Jounce Therapeutics Presents INNATE Phase 1 and SELECT Clinical Trial data at the European Society of Medical Oncology Immuno-Oncology (ESMO - IO) Annual Congress
Nov 10, 2022
Seeking Alpha
Jounce: Jounce Therapeutics, Inc. (JNCE) Q3 2022 Results - Earnings Call Transcript
Nov 02, 2022
GlobalNewswire
Press Release: Jounce : Jounce Therapeutics earns clinical milestone payment under the CCR8 exclusive license agreement with Gilead Sciences, Inc.
Oct 21, 2022
Life Care News
Jounce: Jounce Therapeutics to Present Multiple Posters at the
Aug 31, 2022
Pharmaphorum
Jounce: Jounce setback casts deeper pall over ICOS as cancer target
May 17, 2022
GlobeNewswire
Press Release: Jounce : Jounce Therapeutics to Present at Upcoming Investor Conferences
Looking for similar companies to Jounce?
Jounce Quarterly and Annual Revenue
Coming soon for Jounce!
Annual Revenue
$53.8M
Jounce's revenue is the ranked 1st among it's top 10 competitors. The top 10 competitors average 53.8M.
Jounce News
Jounce Press Releases
Jounce Videos
Jounce Headquarters
Jounce Summary
ABOUT
Overview
Jounce Therapeutics is engaged in the discovery and development of a pipeline of cancer immunotherapy treatments for a range of cancers. Jounce was founded in 2012. Jounce's headquarters is located in Cambridge, Massachusetts, USA 02139. Jounce's Pre...CEO
Jounce's President & CEO, Richard Murray, currently has an approval rating of 77%. Jounce's primary competitors are NexImmune,Website
jouncetx.comCompetitors
View 1 Jounce competitors here.Acquisitions
There have been no acquisitions found related to JounceFunding
View Jounce funding details.Investments
Recent investment data cannot be found related to JounceFrequently Asked Questions about Jounce
When was Jounce founded?
Jounce was founded in 2012Who is Jounce's CEO?
Jounce's CEO is Richard MurrayHow much revenue does Jounce generate?
Jounce generates $53.8M in revenueHow much funding does Jounce have?
Jounce has historically raised $296.1M in funding
Where is Jounce's headquarters?
Jounce's headquarters is in Cambridge Massachusetts, USAHow many employees does Jounce have?
Jounce has 140 employeesWhat sector does Jounce operate in?
Jounce is in BiotechnologyWho are Jounce's competitors?
Jounce's top competitors are NexImmune